Unfortunately, the only small inhibitor available PF-429242 failed to reach clinical applications due to its poor pharmacokinetic properties [137], thus begging for a potent and safe SKI-1/S1P inhibitor as an antiviral to fight such deadly infections [132,155,156,157]. This evidence concerns the gene MBTPS1 and infection.